<?xml version="1.0" encoding="UTF-8"?>
<xml>
<records>
<record>
  <contributors>
    <authors>
      <author>Aragó, M.</author>
      <author>Moreno-Felici, J.</author>
      <author>Abás, S.</author>
      <author>Rodríguez-Arévalo, S.</author>
      <author>Hyroššová, P.</author>
      <author>Figueras, A.</author>
      <author>Viñals, F.</author>
      <author>Pérez, B.</author>
      <author>Loza, M.I.</author>
      <author>Brea, J.</author>
      <author>Latorre, Pedro</author>
      <author>Carrodeguas, José A.</author>
      <author>García-Rovés, P.M.</author>
      <author>Galdeano, C.</author>
      <author>Ginex, T.</author>
      <author>Luque, F.J.</author>
      <author>Escolano, C.</author>
      <author>Perales, J.C.</author>
    </authors>
  </contributors>
  <titles>
    <title>Pharmacology and preclinical validation of a novel anticancer compound targeting PEPCK-M</title>
    <secondary-title>Biomed. pharmacother.</secondary-title>
  </titles>
  <doi>10.1016/j.biopha.2019.109601</doi>
  <pages/>
  <volume/>
  <number/>
  <dates>
    <year>2020</year>
    <pub-dates>
      <date>2020</date>
    </pub-dates>
  </dates>
  <abstract/>
</record>

</records>
</xml>